These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38965384)

  • 1. Recruitment of FBXO22 for targeted degradation of NSD2.
    Nie DY; Tabor JR; Li J; Kutera M; St-Germain J; Hanley RP; Wolf E; Paulakonis E; Kenney TMG; Duan S; Shrestha S; Owens DDG; Maitland MER; Pon A; Szewczyk M; Lamberto AJ; Menes M; Li F; Penn LZ; Barsyte-Lovejoy D; Brown NG; Barsotti AM; Stamford AW; Collins JL; Wilson DJ; Raught B; Licht JD; James LI; Arrowsmith CH
    Nat Chem Biol; 2024 Dec; 20(12):1597-1607. PubMed ID: 38965384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment of FBXO22 for Targeted Degradation of NSD2.
    Nie DY; Tabor JR; Li J; Kutera M; St-Germain J; Hanley RP; Wolf E; Paulakonis E; Kenney TMG; Duan S; Shrestha S; Owens DDG; Pon A; Szewczyk M; Lamberto AJ; Menes M; Li F; Barsyte-Lovejoy D; Brown NG; Barsotti AM; Stamford AW; Collins JL; Wilson DJ; Raught B; Licht JD; James LI; Arrowsmith CH
    bioRxiv; 2023 Nov; ():. PubMed ID: 37961297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation.
    Kagiou C; Cisneros JA; Farnung J; Liwocha J; Offensperger F; Dong K; Yang K; Tin G; Horstmann CS; Hinterndorfer M; Paulo JA; Scholes NS; Sanchez Avila J; Fellner M; Andersch F; Hannich JT; Zuber J; Kubicek S; Gygi SP; Schulman BA; Winter GE
    Nat Commun; 2024 Jun; 15(1):5409. PubMed ID: 38926334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
    Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
    Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
    Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
    Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.
    Johmura Y; Sun J; Kitagawa K; Nakanishi K; Kuno T; Naiki-Ito A; Sawada Y; Miyamoto T; Okabe A; Aburatani H; Li S; Miyoshi I; Takahashi S; Kitagawa M; Nakanishi M
    Nat Commun; 2016 Feb; 7():10574. PubMed ID: 26868148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
    Jaffe JD; Wang Y; Chan HM; Zhang J; Huether R; Kryukov GV; Bhang HE; Taylor JE; Hu M; Englund NP; Yan F; Wang Z; Robert McDonald E; Wei L; Ma J; Easton J; Yu Z; deBeaumount R; Gibaja V; Venkatesan K; Schlegel R; Sellers WR; Keen N; Liu J; Caponigro G; Barretina J; Cooke VG; Mullighan C; Carr SA; Downing JR; Garraway LA; Stegmeier F
    Nat Genet; 2013 Nov; 45(11):1386-91. PubMed ID: 24076604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation.
    Basu AA; Zhang C; Riha IA; Magassa A; Campos MA; Caldwell AG; Ko F; Zhang X
    Nat Chem Biol; 2024 Dec; 20(12):1608-1616. PubMed ID: 38965383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
    Johmura Y; Harris AS; Ohta T; Nakanishi M
    Cancer Sci; 2020 Aug; 111(8):2718-2725. PubMed ID: 32536008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
    Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
    Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
    Tan MK; Lim HJ; Harper JW
    Mol Cell Biol; 2011 Sep; 31(18):3687-99. PubMed ID: 21768309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCF
    Bai J; Wu K; Cao MH; Yang Y; Pan Y; Liu H; He Y; Itahana Y; Huang L; Zheng JN; Pan ZQ
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11754-11763. PubMed ID: 31138683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
    Park JW; Kang JY; Hahm JY; Kim HJ; Seo SB
    Commun Biol; 2020 Aug; 3(1):462. PubMed ID: 32826945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fbxo22 promotes cervical cancer progression via targeting p57
    Lin M; Zhang J; Bouamar H; Wang Z; Sun LZ; Zhu X
    Cell Death Dis; 2022 Sep; 13(9):805. PubMed ID: 36127346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis.
    Liu P; Cong X; Liao S; Jia X; Wang X; Dai W; Zhai L; Zhao L; Ji J; Ni D; Liu Z; Chen Y; Pan L; Liu W; Zhang J; Huang M; Liu B; Tan M
    Cell Death Differ; 2022 Jan; 29(1):1-13. PubMed ID: 34215846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
    Johmura Y; Maeda I; Suzuki N; Wu W; Goda A; Morita M; Yamaguchi K; Yamamoto M; Nagasawa S; Kojima Y; Tsugawa K; Inoue N; Miyoshi Y; Osako T; Akiyama F; Maruyama R; Inoue JI; Furukawa Y; Ohta T; Nakanishi M
    J Clin Invest; 2018 Dec; 128(12):5603-5619. PubMed ID: 30418174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-Box Protein FBXO22 Mediates Polyubiquitination and Degradation of CD147 to Reverse Cisplatin Resistance of Tumor Cells.
    Wu B; Liu ZY; Cui J; Yang XM; Jing L; Zhou Y; Chen ZN; Jiang JL
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting proteasome-dependent degradation of NSP5.
    Zhou Y; Feng W; Yang C; Wei X; Fan L; Wu Y; Gao X; Shen X; Zhang Z; Zhao J
    J Med Virol; 2024 Sep; 96(9):e29891. PubMed ID: 39223933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.